This article has been updated from an earlier version with additional comments from FDA officials and industry stakeholders.

NEW YORK (GenomeWeb) – Over the next decade, the US Food and Drug Administration will phase in its risk-based approach toward regulating laboratory developed tests, the agency announced today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.